Skip to content

Study · Animal study (in vivo) · rat · 2002

5 results

Evidence for a central inhibitory role of growth hormone secretagogues and ghrelin on gastric acid secretion in conscious rats.

Sibilia V, Pagani F, Guidobono F, Locatelli V, Torsello A, Deghenghi R, Netti C

Neuroendocrinology1 Feb 2002Cited by 53 (Europe PMC)

PMID11867937 (opens in a new tab)DOI10.1159/000048225 (opens in a new tab)PepBankPUB-11867937
Publisher pagePubMedAsk about this study
Jump to 5 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

5 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In conscious pylorus-ligated male rats, central hexarelin significantly inhibited gastric acid secretion.

    In plain wordsIn rats, hexarelin given into the brain reduced stomach acid secretion.

    Peptide
    Hexarelin
    Outcome
    DecreaseGastric acid secretion after central hexarelin
    Study

    ratn: not reported in source

    conscious male rats, pylorus ligation (Shay test)
    Outcome group
    Gastrointestinal protection · Gastrointestinal
    Studied dose
    0.1 pmol to 1 nmol/rat · i.c.v. · 3 h after pylorus ligationAs given in this study (rat).

    Source sentences

    Summary
    Central Hexa, EP 40737 and ghrelin administration (from 0.1 pmol to 1 nmol/rat, i.c.v.) significantly inhibited gastric acid secretion.
    1 context sentence
    Summary · context
    The compounds were administered intracerebroventricularly (i.c.v.) or subcutaneously (s.c.) in conscious male rats and the volume of gastric secretion and gastric acid output were examined 3 h after pylorus ligation (Shay-test).
  2. 02AnimalAnimal study (in vivo)Efficacy outcome

    In conscious pylorus-ligated male rats, the maximum inhibition of gastric acid output by central hexarelin was 51.3% at 10 pmol per rat.

    In plain wordsIn rats, hexarelin given into the brain cut stomach acid output most at a low dose.

    Peptide
    Hexarelin
    Outcome
    DecreaseMaximum inhibition of gastric acid output
    Study

    ratn: not reported in source

    conscious male rats, pylorus ligation (Shay test)
    Outcome group
    Gastrointestinal protection · Gastrointestinal
    Studied dose
    10 pmol/rat · i.c.v. · 3 h after pylorus ligationAs given in this study (rat).

    Measurements

    gastric acid output change
    −51.3%
    hexarelin 10 pmol/rat i.c.v.

    Source sentences

    Summary
    The maximum inhibitory effect on gastric acid output was detected at the dose of 10 pmol/rat, i.c.v. for Hexa (-51.3%)
    1 context sentence
    Summary · context
    The compounds were administered intracerebroventricularly (i.c.v.) or subcutaneously (s.c.) in conscious male rats and the volume of gastric secretion and gastric acid output were examined 3 h after pylorus ligation (Shay-test).
  3. 03AnimalAnimal study (in vivo)Efficacy outcome

    In conscious pylorus-ligated male rats, central hexarelin was less effective at the highest dose of 1 nmol per rat.

    In plain wordsIn rats, hexarelin given into the brain worked less well at the highest dose than at lower doses.

    Peptide
    Hexarelin
    Outcome
    MixedDose-response at the highest central dose
    Study

    ratn: not reported in source

    conscious male rats, pylorus ligation (Shay test)
    Outcome group
    Gastrointestinal protection · Gastrointestinal
    Studied dose
    1 nmol/rat · i.c.v. · 3 h after pylorus ligationAs given in this study (rat).

    Source sentences

    Summary
    All peptides were less effective at the highest dose used (1 nmol/rat, i.c.v.).
    1 context sentence
    Summary · context
    The compounds were administered intracerebroventricularly (i.c.v.) or subcutaneously (s.c.) in conscious male rats and the volume of gastric secretion and gastric acid output were examined 3 h after pylorus ligation (Shay-test).
  4. 04AnimalAnimal study (in vivo)Efficacy outcome

    In conscious pylorus-ligated male rats, subcutaneous hexarelin did not modify gastric acid secretion.

    In plain wordsIn rats, hexarelin injected under the skin did not change stomach acid secretion.

    Peptide
    Hexarelin
    Outcome
    No significant changeGastric acid secretion after subcutaneous hexarelin
    Study

    ratn: not reported in source

    conscious male rats, pylorus ligation (Shay test)
    Outcome group
    Gastrointestinal protection · Gastrointestinal
    Studied dose
    Dose not stated · s.c. · 3 h after pylorus ligationAs given in this study (rat).

    Source sentences

    Summary
    Hexa, EP 40737 and ghrelin injected s.c. did not modify gastric acid secretion.
    1 context sentence
    Summary · context
    The compounds were administered intracerebroventricularly (i.c.v.) or subcutaneously (s.c.) in conscious male rats and the volume of gastric secretion and gastric acid output were examined 3 h after pylorus ligation (Shay-test).
  5. 05AnimalAnimal study (in vivo)Mechanism

    In rats pretreated with cysteamine, which depletes endogenous somatostatin, central hexarelin did not inhibit gastric acid secretion.

    In plain wordsIn rats given cysteamine, which lowers the brain's somatostatin, hexarelin given into the brain did not reduce stomach acid.

    Peptide
    Hexarelin
    Outcome
    No significant changeHexarelin effect after somatostatin depletion with cysteamine
    Study

    ratn: not reported in source

    conscious male rats, pylorus ligation (Shay test)
    Comparator
    Rats without cysteamine
    Outcome group
    Gastrointestinal protection · Gastrointestinal
    Studied dose
    10 pmol/rat · i.c.v.As given in this study (rat).

    Source sentences

    Summary
    The inhibitory action of Hexa on gastric acid secretion seems to involve brain somatostatinergic system since Hexa (10 pmol/rat, i.c.v.) did not inhibit gastric acid secretion in rats pretreated (4 h before) with cysteamine (300 mg/kg, s.c.), a depletor of endogenous somatostatin.
    1 context sentence
    Summary · context
    The compounds were administered intracerebroventricularly (i.c.v.) or subcutaneously (s.c.) in conscious male rats and the volume of gastric secretion and gastric acid output were examined 3 h after pylorus ligation (Shay-test).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    13 Oct 2026, 21:44 UTC

    Study results updated

  2. Version 1

    13 Oct 2026, 16:31 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.